Sound Pharmaceuticals' IND Involving Cochlear Implantation Allowed by the FDA

SEATTLE & INNSBRUCK, Austria, May 20, 2024--Sound Pharmaceuticals (SPI) is pleased to announce that it has received FDA notification that its Investigational New Drug Application (IND) may proceed involving SPI-1005 treatment and cochlear implantation (CI). The goal of this Phase 2 SPI-1005 (ebselen) trial is to reduce the loss of residual hearing during and after CI. Ebselen is a novel anti-inflammatory compound that mimics and induces the activity of Glutathione Peroxidase, an enzyme that is c

Related Keywords

United States , Austria , Americans , Jonathan Kil , Nicola Trussell , Erwin Hochmair , Cystic Fibrosis Foundation , Pr Corporate Communications , Sound Pharmaceuticals , Investigational New Drug Application , Glutathione Peroxidase , Fast Track , Principal Investigator , Cystic Fibrosis ,